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1. Introduction
Liver is one of the most important organs in our body and any damage on this vital organ
may be life threatening. Various factors such as toxins, heavy metals, drugs and infection
with hepatitis viruses are able to influence on the function of this organ. One of the most
important effects of these factors on liver is gradual necrosis of active liver cells and if this
disturbance  remained  untreated,  can  lead  to  liver  fibrosis,  cirrhosis  and  finally  death.
Therefore, it is necessary to diagnose the liver fibrosis. Nowadays physicians rely on liver
biopsy to evaluate liver fibrosis. This method was named as ‘gold standard’ for many years,
but it seems researchers prefer to say “The best, not the gold standard”. Because of liver
biopsy limitations (inter-observer variation amongst pathologists, fibrosis staging systems
and sampling errors), patients and also physicians like to estimate the liver fibrosis stages
and inflammation grades noninvasively. Therefore we had to find non invasive markers
for estimation of liver fibrosis stage.
There are various serum based biomarkers, individually or in an algorithm model for estima‐
tion of liver fibrosis stage. The list of serum marker algorithms for assessment of liver fibrosis
is increasing. [1-6]. In the last decade, the list of liver fibrosis noninvasive tools is increased
rapidly. Some of them (such as transient ultrasound elastography [FibroScan], acoustic
radiation force impulse [ARFI], magnetic resonance imaging [MRI], doppler analysis, com‐
puted tomography [CT], real-time elastography, tissue strain imaging, supersonic shear
imaging, diffusion-weighted MRI, magnetic resonance spectroscopy, positron emission
tomography [PET] and single photon emission computed tomography [SPECT] [5-8]) are
beyond the scope of this chapter. In this chapter, we will focus on serum noninvasive algo‐
rithm-based scores surrogate of liver biopsy.
© 2013 Parsian et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
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distribution, and reproduction in any medium, provided the original work is properly cited.
2. List of serum noninvasive algorithm-based scores
There are some serum-based noninvasive markers individually or in an algorithm-based score
that proposed instead of liver biopsy. These markers are usable in clinic, because the physicians
are able to request analysis of them frequently, during the treatment and for assessing the
treatment efficacy, too.
The lists of individual markers are long. The most common of them that are introduced from
the past are: aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin,
alkaline phosphatase, albumin, prothrombin time and gamma glutamyl transferase [2-6]. Now
it is proposed that some of these simple tests are not able to predict liver injury accurately. For
example Seto showed that an elevation of serum ALT levels is not able to predict liver injury [9].
There are some markers that newly introduced and most well-known of them are: α-2-
macroglobulin, apolipoprotein A1, collagen markers such as procollagen I carboxyl terminal
peptide (PICP), procollagen III amino terminal peptide (PIIINP), procollagen IV C peptide,
procollagen IV N peptide (7-S collagen) and collagen IV, collagenases (metalloproteinase) and
their inhibitors (tissue inhibitors of metalloproteinase), glycoproteins such as human cartilage
glycoprotein (YKL-40), fibronectin, laminin, osteonectin, tenascin, glycosaminoglycans such
as perlecan, hyaluronic acid, decorin, aggrecan, lumican, fibromodulin and the others [2-4,
10-12]. Some of these parameters increased in various diseases such as cancer; therefore before
the using of these parameters for estimation of liver fibrosis, we had to exclude the other
diseases [13].
It seems that these serum individual markers are useful for establishing the presence, but not
absence of the fibrosis. For overcome on this problem, researchers combined the results of
panels of markers and proposed various algorithms. Interestingly, in some algorithms improve
in diagnostic accuracy of these noninvasive markers were observed. Again the lists of these
markers are long. Some of the most well-known of them are:
AST to platelet ratio index, Age-platelet index, PGA index, Forns, Bonacini, De Ritis, PATEL,
Leroy, FibroSpect, European Liver Fibrosis score, Fibrometer, Hepascore, SHASTA Index,
FIB-4, SteatoTest, NAFLD Fibrosis Score, Cirrhosis discriminate score, BARD score, Hui
model, FibroMeter NAFLD, Fibrosis Probability Index, Lok index, Fibro Q and the others.
The aim of this chapter is describing the formula, usability and diagnostic accuracy of some
of the most common and available serum noninvasive algorithm-based scores in various liver
diseases in a simple manner.
3. Age-Platelet (AP) index
Age and platelet counts are major constituents of this index. This index is calculated according
to the following instruction:
Platelets counts (109/l): 225 = 0; 200-224 = 1; 175-199 = 2; 150-174 = 3; 125-149 = 4; <125 = 5
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Age (years) <30 = 0; 30-39 = 1; 40-49 = 2; 50-59 = 3; 60-69 = 4; 70 = 5
Sum of age and platelets counts scores are AP index [14]. Various studies proposed that this
index is a good index for estimating liver fibrosis stage. For example in a study that carried
out by Lackner [15] on HCV patients, area under the ROC curve (AUROC) was 0.740 for
prediction of significant fibrosis and for prediction of cirrhosis, AUROC was 0.910 (according
to Ishak score). In another study on 62 hepatitis patients, Parsian et al reported an AUROC of
0.818 for discrimination of patients with liver fibrosis vs. control group and an AUROC of 0.518
for discrimination of patients with mild from those with significant fibrosis [16]. There are
other studies that discussed diagnostic accuracy of this simple index [17].
4. AST to Platelet Ratio Index (APRI)
APRI score was initially described by Wai et al [18]. This index is dependent to two routine
tests, i.e. aspartate aminotransferase and platelet count and simply calculated by this formula:
APRI = (AST, upper limit of normal) / platelet count (109/ L) × 100
Several studies have suggested that the APRI may be a useful noninvasive marker of hepatic
fibrosis. Shin et al showed that in chronic hepatitis B patients, the predictive power of detecting
significant fibrosis based on the AUROC is 0.850–0.950 and concluded that this index is a useful
indirect marker for estimating significant fibrosis [19].
The AUROC of APRI in HCV patients was reported better in female (0.871) than in male (0.753).
Among female cases, an APRI value >1.4 was 91% sensitive and 75% specific in detecting a staging
score >2. The corresponding values among male cases were 60% and 77%, respectively [8].
5. AAR index (Deritis index)
There is another simple index that used for evaluation of liver fibrosis and researchers named
it AAR index. By dividing the levels of two routine enzymes, i.e. AST and ALT, we are able to
calculate it [20].
In a study that carried out on 111 NAFLD patients, researchers found an AUC of 0.61 with an
AST/ALT ratio of 0.8 for the prediction of advanced fibrosis [21]. Park et al reported that AST/
ALT > or = 1 is highly specific but not diagnostic for the presence of cirrhosis in patients with
chronic HCV infection and concluded that the ratio reflects the grade of fibrosis in these
patients [22].
6. Fibro Q
Fibro Q is a index that is more complicated than previous indices and is dependent to age
(years), AST level, platelet count and also PT International Normalized Ratio (INR). PT INR
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measures the extrinsic pathway of coagulation. We are able to calculate this index by the
following formula [23].
Fibro Q = (10 × age (years) × AST × PT INR)/ (PLT × ALT) .
In 2012, Hsieh et al showed that FibroQ is a simple and useful test for predicting significant
fibrosis in patients with chronic hepatitis C [24]. In our previous study, we found that this
index had a reasonable AUROC for discrimination of patients with liver fibrosis vs. control
and not for discrimination of patients with severe liver fibrosis vs. mild liver fibrosis [11].
7. FIB4
Other simple index that related to age (years), AST and ALT levels (U/L) and platelet count,
is FIB-4 [25]. By the following formula, one can calculate its value:
FIB-4 = age (year) × AST (U/L) / PLT (109/L) × ALT (U/L))1/2 .
Yang et al reported that FIB-4 index had a significant power for differentiation between
patients with mild and significant fibrosis in nonalcoholic fatty liver disease (0.24 ± 0.12 vs.
0.31 ± 0.21, P = 0.010) and the AUROC of FIB4 was 0.810. They reported that FIB4 might be
useful as a noninvasive hepatic fibrosis scores for predicting hepatic fibrosis in patients with
NAFLD [6]. Shah et al [8] in a study on 541 NAFLD adults found that among various serum
based algorithms, FIB4 had better diagnostic accuracy for estimation of liver fibrosis.
8. BARD score
In 2008, Harrison et al proposed an index and named it BARD score. The constituents of this
score are body-mass index (BMI), AST/ALT ratio (AAR), and presence of type 2 diabetes
mellitus (DMt2). They combined these three simple variables to propose a score for predicting
advanced fibrosis. Calculating of this score is simple:
BMI ≥ 28 kg/m2 = 1 point, BMI <28 kg/m2 = 0 point; AST/ALT ratio ≥ 0.8 = 2 points, AST/ALT
ratio < 0.8 = 0 points; freshly recognized or preexisting DMt2 = 1 point.
A total of 2-4 points (sum of the score of BMI, AST/ALT ratio and presence or absence of DMt2)
indicate significant fibrosis [26]. In a study that carried out by Wyszomirska in 2010, validation
of this score on nonalcoholic fatty liver disease (NAFLD) evaluated. They reported that this
scoring system has value for diagnosis of advanced fibrosis in NAFLD patients and if it is
possible using of this system in clinic, most patients don’t need to undergo liver biopsy [27].
As another try to determine the validation of this score, Ruffillo et al, evaluated the diagnostic
accuracy of this score in NAFLD patients and concluded that this score is useful in identifying
patients without severe fibrosis [28].
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9. Enhanced Liver Fibrosis (ELF)
This liver fibrosis score is derived from markers that are not available in routine clinical
laboratories [29-30]. It was shown that this score has good diagnostic accuracy for the detection
of moderate and severe fibrosis [31].
ELF panel constituents are matrix metalloproteinase 1 inhibitor, hyaluronic acid, and amino‐
terminal peptide of pro-collagen III.
ELF score can calculate by this formula [32]:
Discriminant score = - 7.412 + ln (HA) × 0.681) + ln (PIIINP) × 0.775) + ln (TIMP1) × 0.494] + 10
In a study that carried out by Nobili et al on 112 NAFLD subjects, concluded that the ELF test
is able to accurately discriminate patients with liver fibrosis and can be used for assessing the
level of liver fibrosis in pediatric patients [30].
10. Cirrhosis Discriminate Score (CDS) Bonacini
This simple score is proposed by Bonacini [33] and its constituents are AST/ALT, PT-INR and
platelet count in a simple manner as described in table 1 [34]. According to this score, different
points are given to ingredients of this index and ultimately they added together.
Table 1. Determinants of Bonacini score.
There are various studies that analyzed the accuracy of this index for assessing liver fibrosis. For
example in a study by Colli et al [34] on 176 patients with chronic HCV infection, they observed
that this score was able to identify 67% of patients with a high (>75%) or low (<10%) probability of
cirrhosis, and ultimately 33% of the HCV patients need liver biopsy for assessing their liver fibrosis
score. Against the above study, there are some studies that found this score was not able to detect
severe fibrosis and observed this score has low power of discrimination [35].
11. Fibrotest (FT)
Fibrotest is consisting of a panel of five biomarkers that proposed for evaluation of liver fibrosis
stage. Constituents of this index are alpha2-macroglobulin, haptoglobin, apolipoprotein A1,
gamma glutamyl transpeptidase and total bilirubin [36] and the formula of this index is:
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Fibrotest=4467 × log [alpha2-macroglobulin (gr/l)] – 1357 × log [haptoglobin (gr/l)] + 0.0821 ×
[age (years)] +1737 × log [bilirubin (μmol/l)] - 1184 × [apolipoprotein A1 (gr/l)] + 0.301 × sex
(male=1, female=0) – 5.054
FT is the most studied test and now there are various studies that proposed this test has
considerable ability for discrimination of liver fibrosis without significant divergence among
liver diseases. For example its ability on hepatitis C, hepatitis B, alcoholic and nonalcoholic
fatty liver disease was shown [37-40].
In a study that carried out by Sebastiani et al [41] the ability of several noninvasive markers
including FT on 110 CHB patients were assessed. They found that the Fibrotest and APRI had
the highest diagnostic accuracy for discrimination of patients with severe stage of liver fibrosis.
In another study on 221 chronic alcoholic liver disease patients, Naveau et al [42] reported that
in heavy alcohol drinkers, this test is able to estimate the liver fibrosis stage and by this test is
possible to decrease the need for liver biopsy.
12. Fibrometer
Fibrometer is a regression algorithm that proposed for evaluation of liver fibrosis stage in liver
diseases. Glucose, AST, ferritin, platelet, ALT, body weight and age are the variables that this
score is derived from them. First time, this score proposed by Cales et al [43]. Calculation of
this score is simple by the following formula:
Fibrometer= 0.4184 glucose (mmol/l) + 0.0701 AST (IU/l) + 0.0008 ferritin (μg/l) - 0.0102 platelet (G/l)
- 0.0260 ALT (UI/l) + 0.0459 body weight (kg) + 0.0842 age (yr) + 11.6226.
Various groups of researchers determined the diagnostic accuracy of this index versus liver
biopsy in liver disease. For example Cale et al [44] analyzed the accuracy of this index on 235
NAFLD patients. They observed that this score, in comparison with the other scores such as
APRI, had higher accuracy rate for significant fibrosis and had lower misclassification rate.
Finally, they concluded that Fibrometer had a reasonable performance.
13. Fibrosis Probability Index (FPI) or sud index
This index is depended on: any history of alcohol use, patient age, cholesterol level, AST
activity and HOMA-IR index (Homeostasis model assessment: insulin resistance) [45]. First
time Sud et al proposed this index and published the results of their study in hepatology
journal [46]. They considered and analyzed thirty-five variables in 176 HCV patients and
proposed a fibrosis probability index (FPI) for estimation of the liver fibrosis stages by some
of these parameters. In addition, they tested the accuracy of this index in another study consists
of 126 patients.
Fibrosis probability index (FPI) = 10.929 + (1.827 × Ln AST) +(0.081 × age) +
 (0.768 × past alcohol use) + (0.385 × HOMA-IR) – (0.447 × cholesterol).
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It seems, this index that proposed by this research team can be used as a noninvasive tools for
estimation of liver fibrosis and this confirmed by others [47].
14. Forns score
Another score for assessing the liver fibrosis score is Forn score [48]. Constituents of this score
are age, platelet count, GGT, and cholesterol. One can calculate this index by this equation:
Forns index: 7.811 - 3.131 × ln(platelet count) + 0.781 × ln(GGT) + 3.467 × ln(age) - 0.014 × cholesterol
In their study on 476 CHC patients, Forn et al reported the AUROC of this score was 0.86 for
the estimation group and 0.81 for the validation group. Yang et al [6] evaluated the accuracy
of Forn score in 77 NAFLD children and according to the severity of their necroinflmmatory
injuries, divided the patients to two groups: mild fibrosis (stage 0-1) vs. significant fibrosis
(stage 2-4). They analyzed diagnostic accuracy of some simple algorhitms such as AAR, APARI
and FIB-4, in addition to Forn score. They observed that among these algorithms, only APRI
and FIB4 had a significant difference between patients with mild and significant fibrosis.
15. Hepascore
Hepascore is a more complicated score for estimation of liver fibrosis stage. Age, gender,
bilirubin, GGT, hyaluronic acid and alpha2-macroglobulin are constituents of this score [49].
In this score that was proposed by Adams et al for the first time, they added a single direct
biomarker of hepatic fibrosis i.e. hyaluronic acid in their algorithm.
By this formula, we can calculate this score:
Hepascore = y/(1 + y), where y = exp (-4.185818 –0.0249 × age + 0.7464 ×gender (male = 1, female = 0) 
+ 1.0039 ×α2-macroglobulin + 0.0302 ×hyaluronic acid + 0.0691 × bilirubin – 0.0012 × GGT.
In their study, Adams et al on 221 HCV patients reported AUROCs of 0.82, 0.90 and 0.89 for
the diagnosis of significant fibrosis, extensive fibrosis and cirrhosis, respectively.
In another study on patients with chronic hepatitis C virus, Becker et al [50] reported that
Hepascore is able to predict liver fibrosis and maybe by this score a need for liver biopsy is
decrease. Bourliere et al reported that the accuracy of Hepascore for excluding the cirrhosis
was excellent [51].
16. HUI model
Hui et al performed a retrospective study on 235 CHB patients and by univariate analysis and
multivariate logistic regression generated this predictive model. They concluded that this model
is able to predict absence of significant fibrosis, accurately. Body mass index (BMI), platelet count,
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serum albumin, and total bilirubin levels are the constituents of this model [52]. Calculation of this
model is very simple and we can calculate this model score by this following formula.
Hui score = 3.148 + 0.167× BMI + 0.088×bilirubin - 0.151× albumin - 0.019 × platelet
In a study that carried out by Sebastiani on 110 CHB patients, some indices such as, APRI,
Forns’ index, Hui’s model and Fibrotest were determined. They reported that performance of
these methods for discrimination of patients with significant fibrosis as positive predictive
values (PPV) was excellent, i.e. 100% for Forns and greater than 92% for APRI, GUCI, Fibrotest
and Hui model [41].
17. Leroy score or MP3 model
Leroy et al used extracellular matrix component i.e. procollagen III amino terminal peptide
(PIIINP) and matrix metalloproteinases-1 (MMP-1) for proposing this model. They determined
serum levels of hyaluronate (HA), PIIINP, MMP-1, MMP-2, MMP-9 and their tissue inhibitors
of metalloproteinases (TIMP-1 and TIMP-2) in 194 chronic hepatitis C patients and 194 healthy
people. They found that six markers (MMP-2, TIMP-1, HA, PIIINP, MMP-1 and MMP-9) were
significantly correlated with liver fibrosis and by using regression model they proposed their
index according to the following formula:
MP3= 0.5903 × log PIIINP (ng/mL) - 0.1749 × log MMP-1 (ng/mL)
They showed that their scoring system is able to differentiate between mild and significant fibrosis
and pointed that maybe this score can provide a useful tool for evaluating liver fibrosis [53].
18. Lok index
Another simple scoring system for estimation of liver fibrosis stage that proposed by Lok et al
is Lok index [54]. This index is based on serum AST and ALT levels, platelet count and PT-
INR. One can calculate this index according to a simple formula:
Lok index = - 5.56 - 0.0089 × platelet (103mm3) + 1.26 × AST/ALT ratio + 5.27 × INR
For this scoring system two cut points introduced: 0.2 to rule out cirrhosis and 0.5 to confirm
cirrhosis. All values that are between these cut points are considered indeterminate. Lok et al
in their cohort study on 1,141 patients with CHC, introduced this score and reported an
AUROC of 0.78-0.81 to detect cirrhosis.
There are various studies that used this score for estimation of liver fibrosis stage. Castera et al
reported that this index has a reasonable performance [55]. Masuzaki studied 386 CHC patients
for determining the diagnostic accuracy of this index in comparison with the other noninvasive
indices such as APRI. They reported that Lok index and APRI were correlated with histological
fibrosis stages (rho=0.581, and 0.460, respectively) and reported an AUROC (95% CI) of Lok index
and APRI of 0.787 (0.741-0.832) and 0.692(0.639-0.745), respectively [56].
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19. FIBROSpect or PATEL index
Patel et al [57] by combing the serum levels of hyaluronic acid (HA), tissue inhibitors of
metalloproteinase 1 (TIMP-1) and alpha2-macroglobulin (A2M), introduced this index that is
also has another name, FibroSpect. Against the much scores that are based on the routine and
simple laboratory tests, this score is based on the specific and non routine laboratory test. In a
study that carried out by their research team on 696 HCV patients, they introduced this scoring
system and reported an AUROC of 0.830 for the diagnosis of significant fibrosis.
There are some studies that confirmed the diagnostic accuracy of this scoring system and
reported the excellency of this scoring system for estimation of liver fibrosis [58].
20. PGA index
PGA index can be calculated by the sum of three tests, i.e., P, prothrombin time; G, gamma-
glutamyl transpeptidase and A, apoliprotein AI and is ranged from 0 to 12 [59].
There are various studies that showed the accuracy of this index in patients with various
chronic liver diseases [60-61]. These studies reported that this score has highest accuracy for
detecting cirrhosis in patients with alcoholic liver disease.
Against the above mentioned studies, Yang et al didn’t find similar results [6]. In their study
on 77 NAFLD children, diagnostic accuracy of PGA index (AUROC=0.45) in addition to the
other tests such as AAR (0.53), APRI (0.70), Forns index (0.73) and FIB-4 (0.81) were compared.
They concluded that among these indices, APRI and FIB4 had the highest performance for
discrimination of patients with mild from significant fibrosis.
21. SHASTA index
This index first time introduced by Kelleher et al [62]. They studied 95 patients that had HIV/
HCV co-infection and determined the serum levels or activity of ALT, AST, APRI, albumin,
total bilirubin, hyaluronic acid (HA) and YKL-40. They observed that among these tests, only
serum HA, albumin and AST were useful for discrimination of mild from advanced fibrosis.
Finally they constructed a predictive model by these factors (HA, albumin and AST) and
named it SHASTA Index. This index can be calculated by the following formula:
Risk score = -3.84 +1.70 (1 if HA 41–85 ng/ml, 0 otherwise) +3.28 (1 if HA>85 ng/ml, 0 otherwise) 
+1.58 (albumin <3.5 g/dl, 0 otherwise) +1.78 (1 if AST >60 IU/l, 0 otherwise).
A cut off of 0.8 of this index showed specificity and positive predictive value of 100%. A cutoff
of <0.30 was associated with a sensitivity and negative predictive value of 88% and 94%,
respectively.
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22. STEATO test panel
This index is an index that proposed by researchers for estimation of liver steatosis in alcoholic,
NAFLD, hepatitis C and B patients. By combining the simple parameters such as age, sex, and
BMI with AST, ALT, bilirubin, GGT, alpha2-macroglobulin, apolipoprotein AI, haptoglobin,
glucose, cholesterol, and triglyceride this index proposed. First time, Poynard et al proposed
this index by the above mentioned variables. They found that steatoTest is able to predict liver
steatosis and can decrease the need for liver biopsy [63].
In a study that carried out by Lassailly, diagnostic accuracy of this panel confirmed on two
hundred and eighty-eight patients with morbid obesity and concluded that this panel is able
to reduce the need for biopsy [64].
23. NAFLD fibrosis score
Components of this score that proposed by Angulo et al are age (years), body mass index,
impaired fasting glucose (IFG) or presence the diabetes, AST, ALT, platelet count, and serum
albumin levels [65]. They proposed this index as a predictive model for estimation of liver
fibrosis. By using the following formula, we are able to calculate this scoring system.
NAFLD fibrosis score =-1.675 + 0.037× age (years) + 0.094 ×BMI (kg/m2) + 1.13 × IFG/diabetes (yes = 1, no = 0) 
+ 0.99 × AST/ALT ratio – 0.013 ×platelets (109/l) – 0.66×albumin (gr/dl)
A score value < -1.455 (lowest cut point) is able to exclude advanced liver fibrosis and a value
> 0.676 (high cutoff) is able to predict advanced liver. Values between these two values are
considered as indeterminate liver fibrosis and maybe patients with this result had to undergo
liver biopsy.
Shah et al studied diagnostic accuracy of this scoring model in 541 adults with NAFLD for
estimation of liver fibrosis and found an AUROC (95% confidence interval [CI]) of 0.768; (0.720
– 0.816) for this model [8]. In another study that carried out by Ruffillo et al on 138 NAFLD
patients, they concluded that this scoring model is useful for identifying patients without
severe fibrosis, but it has some indeterminate results [28]. In another study that carried out by
Yang et al on 77 NAFLD children, AUROC of NAFLD fibrosis score was determined 0.58 for
discrimination of mild from significant liver fibrosis [65].
24. Göteborg University Cirrhosis Index (GUCI index)
First time, this index proposed by Kandemir et al [66].They analyzed blood samples from 68
CHC patients for aspartate aminotransferase, prothrombin INR, and platelet count and found
Practical Management of Chronic Viral Hepatitis100
a strong association between the fibrosis stage and their proposed index. The GUCI index can
be calculate by this formula:
GUCI = Normalized AST× prothrombin-INR ×100 / Platelet count (×109/L)
They concluded that this index can discriminate patients with severe fibrosis (stage 3-4) from
those without severe fibrosis (stage 0-2).
25. King score
This score introduced by Cross et al and is a simple index that derived from age, AST activity
INR and platelet count, as follow for the estimation of liver fibrosis.
King’s Score = age (years) × AST (IU/l) × INR / platelets(109/L)
Cross et al in their study on 923 CHC patients introduced this scoring model. They reported
AUROCs for predicting of cirrhosis and significant fibrosis of 0.91 and 0.79 (respectively) and
the results was confirmed in a validation study. They concluded that this scoring is an
applicable index for predicting of cirrhosis in chronic hepatitis C patients [67].
Diagnostic accuracy of this scoring model determined in another study. Cross et al performed
another study on 187 CHC patients and evaluated the diagnostic accuracy of King score (KS)
model and Fibroscan (FS). For diagnosis of significant fibrosis, AUROCs for FS, KS and FS +
KS were 0.83, 0.82 and 0.85 (respectively) and for the diagnosis of cirrhosis these values were
0.96, 0.89 and 0.93, respectively [68].
26. Predicted Liver Fibrosis score (PLF score)
Bota et al in their study on 212 CHC patients proposed a scoring system for estimation of liver
fibrosis and named it predicted liver fibrosis score [69]. Constituents of their score are transient
elastography (TE), APRI score, Forns score, FIB-4 score and King score. Their scoring formula is:
Predicted liver fibrosis score (PLF score) = 0.956 + 0.084 × TE – 0.004 × King Score + 0.124 × Forns score + 0.202 × APRI score.
They found a good correlation (r = 0.68) for their score with liver fibrosis and concluded that
this complex formula that derived from the other algorithms, is able to predict sever fibrosis
and its performance is better than TE.
The cut off values, AUROC, positive and negative predictive values of the above mentioned
algorithms for estimation of liver fibrosis severity in chronic viral hepatitis and/or NAFLD/
NASH is summarized in the table 2.
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Noninvasive Test Variables Disease Cut off AUROC PPV NPV Explanations
AAR AST and ALT HCV ≥1 NA 73.7 88.1
AP Age and plateletscounts HCV ≥6
t=0.76
v=0.69 96 NA
APRI AST and plateletscounts HCV
≥1.5
≤0.5
t=0.80
v=0.88 91 90
≈Ishak 3-6
≈Ishak 0-2
BARD score
BMI, AST, ALT and
type 2 diabetes
mellitus
NAFLD/
NASH
2-4
2 NA
43
27-81
96
45-95
Advanced liver
fibrosis (F3-4)
CDS PT-INR, AST, ALT andplatelets counts HCV >8 NA 92.6 NA ≈Knodell 3-4
ELF
Matrix
metalloproteinase 1
inhibitor, hyaluronic
acid, and
aminoterminal
peptide of pro-
collagen III
HBV
HCV
NAFLD
>0.102
<0.102 0.8 35 92
≈ Scheuer 3-4
≈ Scheuer 0-2
FIB4 Age, AST, ALT andplatelet count HCV
<1.45
>3.25 0.76 65 90
≈Ishak <4-6
≈Ishak ≥4-6
Fibro Q Age, AST, plateletcount and PT-INR
HBV
HCV
1.6
2.6
F2-4= 0.783
F4=0.791
93
11.3
41
100
Fibrometer
Glucose, AST, ferritin,
platelet, ALT, body
weight and age
NAFLD NA NA 88 92
FIBROSpect
Hyaluronic acid,
tissue inhibitors of
metalloproteinase 1
and alpha2-
macroglobulin
HCV 0.82-0.97 NA 90 58 For stage ≥F2
FORNS SCORE Age, platelet count,GGT, and cholesterol HCV
≥6.9
<4.2
t=0.86
v=0.81 66 96
≈ Scheuer 2-4
≈ Scheuer 0-1
FPI
Alcohol use, age,
cholesterol, AST and
HOMA-IR index
HCV <0.2≥0.8
t=0.84
v=0.77 87 77.4
≈F0-F1
≈F2-F4
FT
Alpha2-
macroglobulin,
haptoglobin,
apolipoprotein A1,
gamma glutamyl
transpeptidase and
bilirubin
HCV
HBV
0.75-1.00 ≈F4
0.73-0.74≈F3-F4
0.59-0.72≈F3
0.49-0.58≈F2
0.32-0.48≈F1-F2
0.28-0.31≈F1
0.22-0.27≈F0-F1
0.00-0.21≈F0
t=0.83
v=0.87
78
76
76
67
61
-
-
-
-
85
91
92
94
Practical Management of Chronic Viral Hepatitis102
Noninvasive Test Variables Disease Cut off AUROC PPV NPV Explanations
Göteborg
University Cirrhosis
Index (GUCI index)
AST,PT-INR, and
platelet count HCV NA F4=0.85 F4=31 F4=97
Hepascore
Age, gender,
bilirubin, GGT,
hyaluronic acid and
alpha2-
macroglobulin
HCV ≥0.5<0.5
t=0.85
v=0.82 88 98
≈F2-F4
≈F0-F1
HUI model BMI, platelet count,albumin and bilirubin HBV <0.15
t=0.803
v=0.765
entire
cohort=0.791
NA NA
King Score Age, AST, INR andplatelet count HCV
≥12.3
≥16.7
F3-6=0.79
F5-6=0.91
81
56
77
96
Leroy score or MP3
model
Procollagen III amino
terminal peptide and
matrix
metalloproteinases-1
HCV NA ≥F2, 0.82 ≥F2=89 ≥F2=84
Lok index AST, ALT, plateletcount and PT-INR HCV NA F4=0.78-.0.81
F4=32
-75
F4=
84-91
NAFLD fibrosis
score
Age, BMI, impaired
fasting glucose (IFG)
or presence the
diabetes, AST, ALT,
platelet count, and
serum albumin levels
NAFLD/
NASH
-1.455
0.676 NA
30-56
82-90
88-93
85-86
PLF score
Transient
elastography, APRI
score, Forns score,
FIB-4 score and King
score
HCV
F ≥ 1= 1.77
F ≥ 2= 2.88
F ≥ 3=2.47
F=4, = 2.98
0.76
0.78
0.86
0.97
99.5
96.4
85.1
70.7
18.1
21.4
78.6
99.4
SHASTA index
ALT, AST, APRI,
albumin, total
bilirubin, hyaluronic
acid and YKL-40
HCV >.08<0.3 0.87 100
94
21.4
Ishak ≥3
Ishak ≤2
STEATO test panel
ALT, α2-
macroglobulin ,
apolipoprotein A-I,
haptoglobin, total
bilirubin, GGT,
cholesterol,
triglycerides, glucose,
age, gender and BMI
NAFLD
0.3
0.5
0.7
NA
22
29
33
100
95
92
For predicting
liver steatosis
greater than
5%.
Table 2. An alphabetical order of various noninvasive serum indices to detect liver fibrosis in patients with chronic viral
hepatitis and/or NAFLD/NASH.
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Abbreviations
AUROC, area under receiver operating characteristic curve; NA, Not available; PPV, positive
predictive value; NPV, negative predictive value; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; MMP, metalloproteinases TIMP, tissue inhibitors of matrix
metalloproteinases; HOMA-IR, homeostasis model assessment of insulin resistance; INR,
international normalized ratio for prothrombie; t, training group; v, validation group [3, 15,
22,23, 52, 63, 67, 69, 71].
27. Conclusion
Liver biopsy still has an important role in the estimation of liver fibrosis stage, but it is not very
far that this invasive method will completely replace with the other noninvasive methods such
as serum based biomarkers [70]. Therefore development of non-invasive methods is still
needed and we should work harder for finding an appropriate method. Maybe with finding
some appropriate biomarkers, we can completely obsolete the liver biopsy.
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